Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

• US 20030021781A1
• Filed: 07/17/2001
• Published: 01/30/2003
• Est. Priority Date: 11/13/1992
• Status: Abandoned Application

• Current Assignee: IDEC Pharmaceuticals Corporation (Biogen, Inc.)
• Original Assignee: IDEC Pharmaceuticals Corporation (Biogen, Inc.)
• Inventors: Hanna, Nabil, Anderson, Darrell R., Rastetter, William H., Reff, Mitchell E., Newman, Roland A., Leonard, John E.
• Application Number:
  US09/905,928
• Publication Number:
  US 20030021781A1
• Time in Patent Office: Days
• US Class Current: 424/144.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 51/1027 against receptors, cell-surface antigens or cell-surface determinants
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2799/028 where the vector is derived from a herpesvirus
• CPC Class Codes: Y10S 424/80 Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
• CPC Class Codes: Y10S 424/801 involving antibody or fragment thereof produced by recombinant dna technology
• CPC Class Codes: Y10S 530/808 Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
• CPC Class Codes: Y10S 530/809 Fused cells, e.g. hybridoma
• CPC Class Codes: Y10S 530/867 involving immunoglobulin or antibody produced via recombinant dna technology

Abstract

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Claims

1. A method for the treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody to a human.

2. The method of claim 1 wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human (“

mg/kg”

).

3. The method of claim 1 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.

4. The method of claim 1 further comprising the step of administering a second therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody.

5. The method of claim 4 wherein said additional administration of said antibody to said human occurs within about seven days of said first administration of said antibody to said human.

6. A method for the treatment of B cell lymphoma comprising the steps of:

1) administering, at a first administration period, a first therapeutically effective amount of immunologically active, chimeric anti-CD20 antibody to a human;

2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;

3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.

7. The method of claim 6 wherein said first, second and third therapeutically effective amount of said antibody is between about 0.001 mg/kg to about 30 mg/kg.

8. The method of claim 6 wherein said second administration period is within about seven days of said first administration period.

9. The method of claim 6 wherein said third administration period is within about fourteen days of said first administration period.

10. The method of claim 6 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).

20. The method of claim 8 when said radiolabeled antibody comprises a monoclonal antibody secreted from a hybridoma identified by American Type Culture Collection deposit number HB 11388.

11. Immunologically active, chimeric anti-CD20 produced from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).

12. A hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collection deposit number HB 11388.

13. A monoclonal antibody secreted from the hybridoma of claim 12.

14. A radiolabeled antibody according to claim 12.

15. The radiolabeled antibody of claim 14 where the radiolabel is selected from the group consisting of yttrium [90];

indium [111], and iodine [131].

16. A method for the treatment of B cell lymphoma comprising of steps of administering a therapeutically effective amount of the antibody of claim 14 to a human.

17. The method of claim 16 when the radiolabel of said antibody is yttrium [90].

18. A method for the treatment of B cell lymphoma comprising the steps of:

1) administering, at a first administration period, an immunology active chimeric anti-CD20 antibody to human; and

2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human.

19. The method of claim 18 when said chimeric anti-CD20 is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.